株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ネフローゼ症候群:パイプライン製品の分析

Nephrotic Syndrome - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 361632
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.11円で換算しております。
ネフローゼ症候群:パイプライン製品の分析 Nephrotic Syndrome - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 46 Pages
概要

ネフローゼ症候群とは、過剰な尿タンパクを排出する腎臓疾患です。ネフローゼ症候群は通常、血液から老廃物と過剰水をろ過している腎臓の微小血管の束が損傷することによって引き起こされます。症状は、過剰な体液鬱滞による浮腫や体重の増加です。危険因子として、糖尿病、紅斑性狼瘡、アミロイド症、HIV、B型肝炎、C型肝炎、マラリア、特定の薬物(非ステロイド性抗炎症剤や抗感染症薬)などがあります。

当レポートでは、ネフローゼ症候群治療薬の開発状況について調査しており、パイプライン製品の概要、治験段階別の製品概要、主要企業および薬剤のプロファイル、パイプライン製品の最新動向、および最新ニュース/プレスリリースなどを提供しています。

イントロダクション

  • 調査範囲

ネフローゼ症候群の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別のパイプライン製品
  • 大学/研究機関別のパイプライン製品
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • AbbVie Inc
  • 旭化成ファーマ
  • Bristol-Myers Squibb Company
  • Orbis Biosciences Inc
  • Retrophin Inc

薬剤プロファイル

ネフローゼ症候群:休止中のプロジェクト

付録

図表

List of Tables

  • Number of Products under Development for Nephrotic Syndrome, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Nephrotic Syndrome - Pipeline by Asahi Kasei Pharma Corp, H2 2019
  • Nephrotic Syndrome - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Nephrotic Syndrome - Pipeline by ChemoCentryx Inc, H2 2019
  • Nephrotic Syndrome - Pipeline by Orbis Biosciences Inc, H2 2019
  • Nephrotic Syndrome - Pipeline by Pharmapraxis, H2 2019
  • Nephrotic Syndrome - Pipeline by SynAct Pharma AB, H2 2019
  • Nephrotic Syndrome - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Nephrotic Syndrome, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11783IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nephrotic Syndrome - Pipeline Review, H2 2019, provides an overview of the Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline landscape.

Nephrotic syndrome is a kidney disorder that causes body to excrete too much protein in urine. Nephrotic syndrome is usually caused by damage to the clusters of small blood vessels in kidneys that filter waste and excess water from blood. Symptoms include severe swelling (edema), foamy urine and weight gain due to excess fluid retention. Risk factors include diabetes, lupus, amyloidosis, HIV, hepatitis B, hepatitis C, malaria, certain medications (non-steroidal anti-inflammatory drugs and drugs used to fight infections).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nephrotic Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 2 respectively.

Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nephrotic Syndrome (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nephrotic Syndrome - Overview
    • Nephrotic Syndrome - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Nephrotic Syndrome - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nephrotic Syndrome - Companies Involved in Therapeutics Development
    • Asahi Kasei Pharma Corp
    • Bristol-Myers Squibb Co
    • ChemoCentryx Inc
    • Orbis Biosciences Inc
    • Pharmapraxis
    • SynAct Pharma AB
  • Nephrotic Syndrome - Drug Profiles
  • Nephrotic Syndrome - Dormant Projects
  • Nephrotic Syndrome - Discontinued Products
  • Nephrotic Syndrome - Product Development Milestones
  • Appendix